Stock Financial Ratios

RGLS / Regulus Therapeutics Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)110.79
Enterprise Value ($M)73.28
Book Value ($M)56.08
Book Value / Share1.06
Price / Book2.28
NCAV ($M)86.85
NCAV / Share1.64
Price / NCAV2.90
Income Statement (mra) ($M)
Net Income-81.84
Balance Sheet (mrq) ($M)
Cash & Equivalents20.22
Cash / Share0.38
Quick Ratio6.34
Current Ratio6.34
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.08
Return on Assets (ROA)-0.81
Return on Equity (ROE)-1.46
Identifiers and Descriptors
Central Index Key (CIK)1505512
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)103.96
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Cash And Equivalents Per Share0.38
Cash Per Share0.38
Equity Per Share0.92
Inventory Finished Goods Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Liabilities Other Non Current Per Share0.01
Property Plant And Equipment Net Per Share0.19
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Liabilities Per Share0.80
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Debt Per Share0.38
Accounts Payable Per Share0.00
Intangibles Per Share0.02
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Liabilities And Stock Equity Per Share1.72
Retained Earnings Per Share-6.28
Assets Current Per Share1.51
Additional Paid In Capital Per Share7.19
Assets Other Non Current Per Share0.01
Inventory Work In Progress Per Share0.00
Liabilities Current Per Share0.22
Assets Per Share1.72
Treasury Stock Per Share0.00
Property Plant And Equipment Per Share0.19
Deferred Income Tax Liabilities Per Share0.00
Assets Other Current Per Share0.03

Stock Research Report

Regulus Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting micro RNAs to treat diseases with significant unmet medical need. Regulus was formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Ionis Pharmaceuticals, Inc., or Ionis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting micro RNAs pursuant to a license and collaboration agreement. Its most advanced program, under its strategic alliance with Sanofi, is RG-012, an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations, currently with no approved therapy available.

micro RNAs are naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown that an imbalance, or dysregulation, of micro RNAs is dire...

Click for full article

Related News Stories

Is It Time To Follow Insiders Into Reata Pharmaceuticals?

2017-12-19 seekingalpha
Results for bardoxolone methyl in treating chronic kidney disease caused by Alport syndrome were highly promising. (46-5)

Regulus Therapeutics' (RGLS) CEO Jay Hagan on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good afternoon. My name is Sonya and I will be your conference operator today. At this time, I would like to welcome everyone to the Regulus Therapeutics third quarter 2017 conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you. (41-5)

PepsiCo (PEP) Q3 Earnings Beat Estimates, Revenues Lag

2017-10-04 zacks
PepsiCo, Inc. (PEP - Free Report) is one of the largest food and beverage business in North America and the second largest in the world. The company boasts a diverse portfolio, both geographically and product wise. Its principal brands/businesses include: Frito-Lay snacks, Pepsi-Cola beverages, Gatorade sports drinks, Tropicana juices and Quaker foods. The company has the competitive advantage of selling both snacks and beverages which are complementary food categories. (59-0)

Paychex (PAYX) Tops Q1 Earnings and Revenue Estimates

2017-10-03 zacks
Paychex, Inc. (PAYX - Free Report) is a leading provider of comprehensive payroll and integrated human resource and employee benefits outsourcing solutions to small- and medium-sized businesses in the United States. Paychex’s payroll service continues to perform well and the company continues to see better-than-expected demand for its human resource outsourcing services. (45-0)

Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

2017-10-03 zacks
Regulus Therapeutics (RGLS - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 37.5% in the past one-month time frame. (49-1)

CUSIP: 75915K101